Literature DB >> 11401897

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention.

M S Niederman, L A Mandell, A Anzueto, J B Bass, W A Broughton, G D Campbell, N Dean, T File, M J Fine, P A Gross, F Martinez, T J Marrie, J F Plouffe, J Ramirez, G A Sarosi, A Torres, R Wilson, V L Yu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11401897     DOI： 10.1164/ajrccm.163.7.at1010

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  428 in total

1.  Managing community-acquired pneumonia.

Authors:  J G Bartlett
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

2.  Antibiotic prescribing: can we make it easier?

Authors:  Scott Flanders; Ralph Gonzales
Journal:  J Gen Intern Med       Date:  2002-02       Impact factor: 5.128

3.  Understanding the potential role of statins in pneumonia and sepsis.

Authors:  Sachin Yende; Eric B Milbrandt; John A Kellum; Lan Kong; Russell L Delude; Lisa A Weissfeld; Derek C Angus
Journal:  Crit Care Med       Date:  2011-08       Impact factor: 7.598

4.  How do we optimize outcomes for patients with severe community-acquired pneumonia?

Authors:  Michael S Niederman
Journal:  Intensive Care Med       Date:  2002-08       Impact factor: 17.440

5.  Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study.

Authors:  W S Lim; M M van der Eerden; R Laing; W G Boersma; N Karalus; G I Town; S A Lewis; J T Macfarlane
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

6.  Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia.

Authors:  V Erard; O Lamy; P-Y Bochud; J Bille; A Cometta; T Calandra
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-01-15       Impact factor: 3.267

7.  Moxifloxacin for community-acquired pneumonia.

Authors:  Bart J A Rijnders
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

Review 8.  Economic aspects of pneumococcal pneumonia: a review of the literature.

Authors:  Diana De Graeve; Philippe Beutels
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 9.  Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

Authors:  Susan J Keam; Katherine F Croom; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

10. 

Authors:  J E Losa García; M R Martín de Cabo
Journal:  Medicine (Madr)       Date:  2013-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.